A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms IMbrave151
- Sponsors Roche
- 20 Jan 2024 Results of updated clinical data and molecular correlates of response and resistance presented at the 2024 Gastrointestinal Cancers Symposium
- 07 Oct 2023 This trial has been completed in Poland.
- 03 Oct 2023 Status changed from active, no longer recruiting to completed.